Pharmaceutical Technology40m
Human papillomavirus (9-valent) vaccine by Xiamen Innovax Biotech for Human Papillomavirus Infections: Likelihood of Approval
Human papillomavirus (9-valent) vaccine is under clinical development by Xiamen Innovax Biotech and currently in Phase II for Human Papillomavirus Infections.
Pharmaceutical Technology28m
Zigakibart by Novartis for IgA Nephropathy (Berger’s Disease): Likelihood of Approval
Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).
Pharmaceutical Technology28m
Danazol by Viramal for Endometriosis: Likelihood of Approval
Danazol is under clinical development by Viramal and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 30% phase transition success rate (PTSR) ...
Pharmaceutical Technology28m
Novaferon by Genova Biotech for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Novaferon is under clinical development by Genova Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).
Pharmaceutical Technology34m
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Solid Tumor: Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Solid Tumor.
Pharmaceutical Technology42m
Bevacizumab biosimilar by Chia Tai Tianqing Pharmaceutical Group for Cervical Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Cervical Cancer.
Pharmaceutical Technology32m
CFTX-1554 by Eli Lilly and Co for Peripheral Neuropathic Pain: Likelihood of Approval
CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.
Pharmaceutical Technology41m
Icerguastat by InFlectis BioScience for Charcot-Marie-Tooth Disease Type I B: Likelihood of Approval
Icerguastat is under clinical development by InFlectis BioScience and currently in Phase I for Charcot-Marie-Tooth Disease Type I B.
Pharmaceutical Technology41m
S-95024 by Les Laboratoires Servier for Non-Small Cell Lung Cancer: Likelihood of Approval
S-95024 is under clinical development by Les Laboratoires Servier and currently in Phase II for Non-Small Cell Lung Cancer.
Pharmaceutical Technology39m
HPG-1860 by Hepagene Therapeutics Shanghai for Inflammatory Bowel Disease: Likelihood of Approval
HPG-1860 is under clinical development by Hepagene Therapeutics Shanghai and currently in Phase I for Inflammatory Bowel Disease.
Pharmaceutical Technology34m
Onvapegleukin alfa by Ascendis Pharma for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer.
Pharmaceutical Technology41m
MB-108 by Mustang Bio for Recurrent Malignant Glioma: Likelihood of Approval
MB-108 is under investigation for the treatment of recurrent glioblastoma multiform, malignant glioma, anaplastic astrocytoma and gliosarcoma. The therapeutic candidate is a next-generation HCMV/HSV-1 ...